World’s Fastest PCR-Based SARS-CoV-2 Test Now Available on Randox-Bosch Vivalytic POC Analyzer
By HospiMedica International staff writers Posted on 29 Oct 2020 |
Image: World’s Fastest PCR-Based SARS-CoV-2 Test Now Available on Randox-Bosch Vivalytic POC Analyzer (Photo courtesy of Bosch Healthcare)
A rapid new coronavirus test, which provides results for COVID-19 in just 39 minutes, is now available on the Vivalytic, a point of care platform brought to market by Randox Laboratories (Crumlin, UK) and Bosch Healthcare (Waiblingen, Germany).
The test for detection of the SARS-CoV-2 pathogen, is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centers at service stations or in airports, so that people who take the test can obtain a reliable result while at the testing site. The advantages of the rapid SARS-CoV-2 test on Vivalytic lie not only in speedy analysis, but also in ease of use. A sample is taken from the nose or throat using a swab, and placed in the test cartridge. Then the cartridge, which contains all the reagents required for the test, is inserted into the Vivalytic device for automated analysis. Available now in Europe, the CE-approved test, which has a sensitivity of 98% and a specificity of 100%, helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.
“Rapid and accurate testing plays a crucial role in identifying cases of Covid-19 – to contain any outbreaks and limit the spread of the virus,” said Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences. “This new rapid test will be a game-changer in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than ever before.”
“With our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device - from screening all the way to supporting differential diagnosis for similar symptoms,” added Marc Meier, president of Bosch Healthcare Solutions GmbH.
The test for detection of the SARS-CoV-2 pathogen, is currently the fastest PCR test (the gold standard of test methods) worldwide, and is predestined for decentralized use in mobile test centers at service stations or in airports, so that people who take the test can obtain a reliable result while at the testing site. The advantages of the rapid SARS-CoV-2 test on Vivalytic lie not only in speedy analysis, but also in ease of use. A sample is taken from the nose or throat using a swab, and placed in the test cartridge. Then the cartridge, which contains all the reagents required for the test, is inserted into the Vivalytic device for automated analysis. Available now in Europe, the CE-approved test, which has a sensitivity of 98% and a specificity of 100%, helps avoid time in quarantine, relieve laboratories, and make travel and work safer again.
“Rapid and accurate testing plays a crucial role in identifying cases of Covid-19 – to contain any outbreaks and limit the spread of the virus,” said Dr. Heather McMillan, Molecular R&D Manager at Randox Biosciences. “This new rapid test will be a game-changer in the coronavirus testing landscape by allowing patients to receive their results at the point of care faster than ever before.”
“With our different coronavirus tests and variable analysis strategies, we open up a range of testing scenarios with a Vivalytic device - from screening all the way to supporting differential diagnosis for similar symptoms,” added Marc Meier, president of Bosch Healthcare Solutions GmbH.
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans